All Rights Reserved. But, as it often does, chance overrode plan, and they both fell in love with the property on the first visit. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. Carl Ashley Morris who sold 441 units worth Peter Kolchinsky, Ph.D. In total, Peter Kolchinsky has made about 2 transactions recently at Mineralys Therapeutics, Inc. Enjoy a 7-Day Free Trial Thru Mar 12, 2023! The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Let us know if you like it and we may post more pieces with this option.) RA Capital is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are . The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Peter Kolchinsky. The singer-songwriter and actress is the latest celebrity addition to Merz Aesthetics Beauty on Your Terms campaign for Botox rival Xeomin. Peter Kolchinsky owns about 1,311,247 units of Mineralys Therapeutics, Inc common stock. Come and visit me at the Pacific Water Conference, booth 520! This investment adviser does not provide advice to individual investors. Franklin Resources Inc, Health Care. He served on the Board of Global Science and Technology for the National Academy of Sciences from 2009 to 2012, is the author of "The Great American Drug Deal" and "The Entrepreneurs Guide to a Biotech Startup", and frequently writes and speaks on the future of biotechnology innovation. Currently GuruFocus does not have mailing address information for Kolchinsky Peter. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. In addition to The Great American Drug Deal, he is the author of The Entrepreneurs Guide to a Biotech Startup. Peter Kolchinsky owns over 4,000,000 units of Wave Life Sciences stock worth over $37,758,818 and over the last 9 years he sold WVE stock worth over $58,095,632. Ignoring warning calls from pharma companies and the Association of the British Pharmaceutical Industry (ABPI), the UK government announced its planning to raise the revenue clawback rate paid by pharmaceutical companies on the Statutory Scheme for Branded Medicines from 24.4% to 27.5%. Data from the new InnoLead/KPMG US Warren Buffett has made it clear. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Most recently he bought 6,337,135 units of KALA stock worth $49,999,995 on 13 March 2020 . Peter Kolchinsky's largest purchase order was, In total, Peter Kolchinsky has made about, Mineralys Therapeutics, Inc's most recent insider trade came on February 16, 2023 by and bought an estimated value of $64.19M worth of shares. The RA Capital Nexus Fund closed at just over $300 million, they said in a statement. . Insider trading is most common in February, with the busiest year in 2023. They fell in love with the historic character and natural beauty of the area and, as they met more of the towns residents, realized that Woodstock was a community that they would like to be part of. No. Keri is currently the Chair of the Religious Studies department at St. Pauls School for Girls in Baltimore, Maryland. The most recent stock trade was executed by Chandra Vargeese on 16 February 2023, trading 10,249 units of WVE stock currently worth $41,303. In the last 16 years, insiders at Dyne Therapeutics, Inc have sold an estimated value of $1.64B Ben Ford was born and raised in Ames, Iowa. This . The most active insiders traders include Capital Management, L.P.Ra , Capital Management, Llc Kol und Peter Kolchinsky. Sign up here. The estimated Net Worth of Peter Kolchinsky is at least $105 Milion dollars as of 23 June 2020. Peter Kolchinsky Oct 5, 2018 Direct-to-Consumer (DTC) advertising: misnamed, misunderstood, and underappreciated Maligned by doctors and often parodied, appropriately regulated. foundation had somehow failed patients by allowing Vertex to price its drugs so high that a 10 percent royalty could be worth so much. As the Independent Director of Wave Life Sciences, the total compensation of Peter Kolchinsky at Wave Life Sciences is $151,598. He studied philosophy at Oregon State University and then earned a law degree from the University of Oklahoma. Generic drugs are more often than not the unsung heroes in healthcare, generating billions in savings every year and increasing access to vital new medicines as the brand-name versions come off patent. The estimated net worth of Peter Kolchinsky is at least $1.2 Billion dollars as of 2023-02-17. Early Life Peter Kolchinsky was born in the United States of America. The Voluntary Scheme for Branded Medicines Pricing and Access is the second option, and typically has lower rates and is negotiated between the government and pharmas. $20M on February 16, 2023. Dr. Kolchinsky is a founder and Managing Partner of RA Capital Management, L.P., a multi-stage investment manager which is dedicated to evidence-based investing in healthcare and life science companies that are developing drugs, medical devices, and diagnostics, where he has worked since 2001. Please note GuruFocus will not track the insiders transaction performance if he/she does not have buying transactions. Peter Kolchinsky usually trades in December, with the busiest year in 2022. Dr. Kolchinsky's RA Capital held 9 million Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) shares worth $208.9 million which represented 2.89% of its portfolio during Q3. Peter Kolchinsky is 43, he's been the Independent Director of Wave Life Sciences since 2015. RA Capital Management, L.P. is the investment manager of RA Capital Healthcare Fund, L.P. She has a Masters in theological studies from Harvard Divinity School and began doctoral work in Buddhist studies at the University of California, Berkeley. I am on Oahu until Friday, so please feel free to also contact me directly in order to discuss Internal digital and data science expertise is critical to developing a united value proposition that aligns the benefits of the digital and medicinal product. He currently works with the State and Local Government Practice Group of the consulting firm Accenture. Anna maintains relationships with many people -- family . Unlock this story instantly and join 161,900+ biopharma pros reading Endpoints daily and it's free. If you're already an Endpoints subscriber, enter your email below for a CB Rank (Investor) 53,342 Primary Job Title Portfolio Manager and Managing Director Primary Organization RA Capital Management Location Boston, Massachusetts, United States Regions Greater Boston Area, East Coast, New England Gender Male Investor Type Investment Partner LinkedIn View on LinkedIn The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. Welcome to the official Blue Horse Inn blog! Please note this link is one-time use only and is valid for only 24 hours. 2001 - Present22 years. March 31, 2020. Covid-19. If you are considering starting your own biotech company, you will appreciate the wealth of practical information packed into The Entrepreneur's Guide to a Biotech Startup. Track performance, allocation, dividends, and risks, Annotate, download XLSX & look up similar tables, Filter, compare, and track coins & tokens. Couple Number Two: Ben Ford and Keri Cole: Ben Ford was born and raised in Ames, Iowa. He currently manages a fund that invests in healthcare and biotechnology companies. Arab Health 2023? Peter Kolchinsky's largest purchase order was, In total, Peter Kolchinsky has made about, Dyne Therapeutics, Inc's most recent insider trade came on January 23, 2023 by Peter Kolchinsky and Raj Shah raise a $300M fund devoted to biotech startups John Carroll Editor & Founder Josh Resnick RA Capital Peter Kolchinsky and Raj Shah have another $300. Catalys Pacific Fund Lp, Peter's mailing address filed with the SEC is C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON, MA, 02116. The outspoken and occasionally caustic Kolchinsky is partnered with an urbane and widely-liked Shah. Kolchinsky Peter Ownership Network Ownership Network List of Kolchinsky Peter Name Position Linked company No Data Ownership Network Relation of Kolchinsky Peter Kolchinsky Peter Mailing Address Above is the net worth, insider trading, and ownership report for Kolchinsky Peter. It was simply awesome! The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. When developed in combination with a medicinal asset, digital therapeutics enable significant market differentiation and significant benefits for stakeholdersfrom optimizing patient outcomes to supporting more efficient generation of compelling real-world data It was written by our very kind neighbor, Hasse K. Halley. Here we are at the BHI after a day of ripping out tile and installing shoe molding: And heres an article about us from The Vermont Standard that we thought you might enjoy. Hedge Fund Net Worth $4.93B Peter Kolchinsky manages more assets than 43% of other Hedge Fund Managers Average Return +0.32% Since Last Filing Last 12 Months 3 Years (Annualized) Portfolio Breakdown by Sector Portfolio Breakdown 97.31% Healthcare 1.12% Services 0.78% Technology 0.51% Financial RA Capital Management Portfolio Activity Company Name This new fund of theirs arrives well into a go-go era of new startup financing, with a particular focus on building new biotechs. Peter Kolchinsky grew up in the Boston area, studied biology at Cornell, and has a PhD in Virology from Harvard. One hopeful voice is biotech investor Peter Kolchinsky, the founder of RA Capital Management. https://t.co/y9IG2Z5txl" Peter Kolchinsky's largest purchase order was 3,178,476 units , worth over Currently GuruFocus does not have mailing address information for Kolchinsky Peter. Anna and Peter originally hoped to find a vacation home that was big enough to share with friends and family and looked at the inn more out of curiosity than with any real intention to purchase it. Peter Kolchinsky owns over 4,000,000 units of Wave Life Sciences stock worth over $38,029,167 and over the last 9 years he sold WVE stock worth over $58,095,632. How do you see re-infections? We loved the idea of having a second home that was also an inn, but we figured our friends and family would try to talk us out of it, said Anna. Things here have been busy; were working hard to get the inn ready for our June 2010 grand opening. The company hired hundreds of new employees and paid . The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. December 22nd, 2014. . Please note the magic link is He is active in both public and private investments in companies developing drugs, medical devices, diagnostics and research tools and serves as a board member for various public and privately-held . It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. You are looking for the virus through an RT-PCR test. Dr. Kolchinsky earned his Ph.D. in virology from Harvard University and earned his bachelors degree in Biology from Cornell University. Anna and Peter discovered Woodstock through Annas participation at the GMHA dressage events. The most active traders at the company are On average, Peter trades about 366,737 units every 19 days since 2014. This ground-breaking new book, The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines (January 20, 2020), by Peter Kolchinsky, PhD, examines the healthcare landscape through the lens of the biotech social contract with America - the implicit agreement between the biopharmaceutical industry and American society - including the government's role in inventing . Peter Kolchinsky / Published in City Journal / February 24, 2020 "Some health economists, such as those at the Institute for Clinical and Economic Review (ICER), believe that they can tell us the right price to pay for each new medicine that the FDA approves. GuruFocus.com is not operated by a broker or a dealer. Alfredo Naj Domingos prostate cancer was spreading. The real solution to affordability is hidden in plain sight amidst all the rhetoric about drug prices. In . At least three dozen biotechs let employees go so far this year, based on Endpoints News reporting, with more having done so under the radar. The oldest executive at Wave Life Sciences Ltd. is KojiMiura, 71, who is the Independent Director. var _Hasync=_Hasync||[];_Hasync.push(['Histats.start','1,4553220,4,511,95,18,00000000']);_Hasync.push(['Histats.fasi','1']);_Hasync.push(['Histats.track_hits','']);(function(){var hs=document.createElement('script');hs.type='text/javascript';hs.async=true;hs.src=('//s10.histats.com/js15_as.js');(document.getElementsByTagName('head')[0]||document.getElementsByTagName('body')[0]).appendChild(hs);})(); Peter Kolchinsky is a famous person who is known worldwide for his work. Peter Kolchinsky's largest purchase order was 2,805,045 units , worth over Nexus is expected to participate in substantially all investments in private companies made by RA Capital alongside its main, longstanding fund, RA Capital Healthcare Fund L.P. Executives behind AI and precision medicine startup Tempus are putting together another AI outfit in Chicago focused on oncology drug discovery and development. The current estimated net worth of Dyne Therapeutics, Inc's Peter Kolchinsky is estimated to be about $2.88B . Carl Ashley Morris, Chief Scientific Officer, You can see the complete history of Peter Kolchinsky stock trades at the bottom of the page. Integrating digital therapeutics early in the asset development process will allow for gathering of clinical data to drive a clearer value proposition that maximizes the potential of both products All Rights Reserved. A hike is also under consideration for the voluntary scheme. He co-founded and runs the Boston-based investment firm RA Capital Management, writes and teaches about biomedical entrepreneurship and its potential to transform global health, serves on the boards of several public and private drug development companies, and has served on the Board of Global Science and Technology for the National . Peter Kolchinsky owns over 4,000,000 units of Wave Life Sciences stock worth over $46,860,585 and over the last 8 years he sold WVE stock worth over $58,095,632. The higher rates are proposed to kick in on April 1. , Keri said, adding that she hopes the new business still allows her some time for her own writing. Tweet With huge thanks to RA Capital's Alex Martinez-Forte and Jacqueline Rhuda for extensive data analysis. Peter served on the Board of Global Science and Technology for the National Academy of Sciences and writes about the biotech social contract. While high-priced branded drugs make up only 11% of all prescriptions, they are the source of most pharmaceutical revenue ($237 billion in 2015). Stock quotes provided by InterActive Data. New to Endpoints? So they invited their close friends Keri and Ben up for what they, Keri and Ben, long-time city dwellers, were, new dream and a substantial life-style change, One of my favorite paintings is from the Blue Horses, , and, of course, horses were what brought the couple to Woodstock. Peter, Anna, Ben and Keri can be found busily working at The Blue Horse Inn most weekends, often with friends and family, and invite the neighbors to stop in and say hello. Boston, MA. To their delight, Keri and Ben, long-time city dwellers, were immediately taken with the town and the inn, and they, too, embraced the vision of a life filled with New England hospitality, nature, and, adds Ben, equal parts fly fishing and snow shoveling. According to world-renowned virologist Peter Kolchinsky, the SARS-CoV-2 virus is nothing short of an "evil genius". Downloadable as a .pptx file. Source: https://www.sec.gov/Archives/edgar/data/1818794/000119312521116286/d937458ddef14a.htm. But there was a lot of adjusting to do, for everyone in the family. we figured our friends and family would try to talk us out of it, said Anna. More There are 12 executives at Wave Life Sciences getting paid more, with PaulBolno having the highest compensation of $3,581,530. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. In support of his arguments, he shared insights from government and industry professionals and cited facts and figures on the trajectory of the drug market. These two energetic couples are living their dream with energy, imagination, creativity and a whole lot of. Past performance is a poor indicator of future performance. Both Moffitt Cancer Center and Mayo Clinic in Florida, not too far from Domingos and his family, said he would have to wait between three and a half and four months to get the treatment. These were worth $145 million and represented 2% of its portfolio. The name for the inn was Annas inspiration; The Blue Horse Inn speaks both to her German heritage and her love of art and horses. Verified account Protected Tweets @; Suggested users Solid Biosciences Inc's most recent insider trade came on January 31, 2023 by A quarters-long flurry of layoffs has caused thousands of workers in life sciences to go hunting for their next position sooner than expected, and the latest wave could make it more difficult to get new offers in hand in short order. Endpoints News Top biotech investor Peter Kolchinsky tees up a new SPAC 3 days after a $300M raise for radiopharmaceuticals play News Dec 9, 2020 Endpoints News RA Capital backs Oxford spinout PepGen with a $45M Series A, seeking to treat Duchenne and other similar diseases as vibrant from the outside as it is on the inside. Past performance is a poor indicator of future performance. Shes currently earning her PhD in European History at Boston College. NEW ORLEANS Esperion Therapeutics revealed long-awaited data on its heart pills efficacy in cutting severe cardiovascular outcomes, three years after the drug was cleared for use to lower cholesterol levels. Peter Kolchinsky owns about 10,916,567 units of Solid Biosciences Inc common stock. In the last year at Solid Biosciences Inc, Peter Kolchinsky has sold an estimated value of $0 worth. The current estimated net worth of Mineralys Therapeutics, Inc's Director, Peter Kolchinsky, is estimated to be about $2.92B . For a patient who can't afford a $5,000 deductible, even slashing a $50,000 treatment's price by 90% would still leave that patient unable to afford his or her $5,000 out-of-pocket obligation. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in Massachusetts with his historian/equestrian wife, strong-willed children, and Kolchinsky who spoke to senior editor Shiv Aroor as part . The drug industry stands accused of charging too much. The Statutory Scheme, which is governed under UK law, is one of two that companies can use. In the interim, they plan to invite, Were not in a rush, Anna explained, and want to take some time to get to know the. The fund was seeded by Vertex Pharma co-founder Rich Aldrich, who invested $4 million at . Dr. Peter Kolchinsky Ph.D. serves as Independent Director of the Company. His wife, Nora Flor, said she and her sister made calls to at least 30 centers across the US looking for the drug. Were not in a rush, Anna explained, and want to take some time to get to know the town. Managing Partner | RA Capital Management Peter is a founder and Managing Partner at RA Capital Management, active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. Bens got me beat so far by three perch and a bass and Im trying to catch up. A biotech analyst bets Novavax has the best data. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in Massachusetts with his historian/equestrian wife, strong-willed children, and reasonably well-trained dog. $5M . January 3, 2023 Feb 10th, Ed. The Great American Drug Deal was released on January 20, 2020. America is rightfully outraged when patients cant afford the medicines they need. Dyne Therapeutics, Inc's most recent insider trade came on January 23, 2023 by I don't believe that temperature plays a role in the spread of Covid-19. But many people worry that Covid-19 will mutate and . . Jonathan McNeill who sold 10,000 units worth Anna is ex, cited about introducing her dressage horse, Im looking forward to some fishing. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. Required fields are marked *. In the last 5 years, insiders at Solid Biosciences Inc have sold an estimated value of $9.83M In a 2018 article, Eric Bender argued that cancer drugs aren't worth the price we pay for them and recommended legislative measures be taken to align prices with the values drugs provide. The current estimated net worth of Dyne Therapeutics, Inc's Peter Kolchinsky is estimated to be about $2.7B . In the companys CLEAR study of nearly 14,000 patients, Esperions drug Nexletol cut the combined risk of heart attack, stroke, cardiovascular death or the need for coronary revascularization by 13%, compared with placebo. Gurus may be added or dropped from the GuruFocus site at any time. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Lefkofsky co-founded Groupon, is a trustee of many marquee Chicago institutions and co-manages the Midwest VC firm Lightbank, which is currently looking to raise $250 million for its third fund, per another document filed with the SEC last November. hope that what we do with the inn will come to reflect the spirit of this wonderful community. Over the last 8 years, insiders at Wave Life Sciences have traded over $18,606,802 worth of Wave Life Sciences stock and bought 14,319,108 units worth $106,704,225 GuruFocus.com is not operated by a broker or a dealer. worked in film production in Berlin for several years before returning to Boston, where she met Peter. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Ben, a storyteller and football aficionado, looks forward to evenings of camaraderie with locals and inn guests. Other family members and associates include Alexander Kolchinsky, Evelina Kolchinsky, Anna Kolchinsky, Joseph Kolchinsky and Joseph Kolchinsky. Well be posting shots of the different projects around the inn in the coming weeks, but first we thought you might like to know a little bit about us. Enjoy a 7-Day Free Trial Thru Mar 12, 2023! Peter Kolchinsky, RA Capital's founder and managing partner, joins to talk about why so many of the policy ideas floated around drug-pricing are wrongheaded. In the years Mineralys Therapeutics, Inc was active, insiders at Mineralys Therapeutics, Inc have bought an estimated value of $0 worth of shares. They will be in plain English and use colorful analogies." These are the three biggest challenges for innovators in large organizations and the three biggest enablers of success. Let us know who we should consider our main ask is that you make the nominations personal. Many proposed solutions, including drug price controls, threaten to defund innovation but also distract the public from the real problem, which lies in the unraveling of the biotech social contract the implicit agreement between the biopharmaceutical industry and American society. Peter Kolchinsky is a founder, Portfolio Manager, and Managing Director at RA Capital Management, LLC, a multi-stage investment manager dedicated to evidence-based investing in healthcare and. It will take some time, but rest assured: a coronavirus vaccine is coming, and it will work. Peter Kolchinsky started RA Capital Management after completing his Ph.D. in virology from Harvard in 2001. Your email address will not be published. Nominations are now open for a special report that will highlight the contributions of LGBTQ+ biopharma leaders. May 27, 2022 (This is a long piece; click here to read it in Bionic Reading format, which may for some increase reading speed and comprehension. Come and visit me at the Pacific Water Conference, booth 520! In addition, they want, Coming from diverse backgrounds and interests, the foursome. He currently manages a fund that invests in healthcare and biotechnology companies. Save my name, email, and website in this browser for the next time I comment. Change), You are commenting using your Twitter account. Mineralys Therapeutics, Inc's most recent insider trade came on February 16, 2023 by Couple Number One: Peter and Anna Kolchinsky: Peter Kolchinsky grew up in the Boston area, studied biology at Cornell, and has a PhD in Virology from Harvard. Add it to the rest of the money and their private deal capacity jumps to $1 billion, with $2.5 billion under management. In the interim, they plan to invite local folks in to see the changes, try out some wines, and make new friends. Change), You are commenting using your Facebook account. The largest trade he's ever made was buying 4,545,455 units of Wave Life Sciences stock on 11 December 2018 worth over $50,000,005. During. The two announced Monday morning that theyve put together their first pure-play venture fund at RA Capital Management, which has been known to bet on just about every angle in healthcare investing from rounds to follow-on investments at public companies. Sometimes Anna goes by various nicknames including Anna H Kolchinsky, Anna I Haas, Anna Haas Kolchinsky and Anna Haas Kolchinsky. Peter Kolchinsky is a founder, Portfolio Manager, and Managing Director at RA Capital Management, LLC, a multi-stage investment manager dedicated to evidence-based investing in healthcare and. Endpoints News connected with the new chair of the generic industrys Association for Accessible Medicines, Christine Baeder, who is also Tevas COO, via video conference on Friday. Novartis can't make enough of it, Q&A with Christine Baeder, new chair of the generic industrys AAM, UK government plans to hike revenue clawback rates beginning in April, Merz Aesthetics hands the mic to Christina Aguilera in Botox rival campaign. She received her bachelors degree from Furman University in South Carolina in Philosophy and Asian Studies. What an undertaking! The foursome plans to open for guests in the late spring of 2010. These . Hard work has helped him rise to the top. and Ian F Smith, Director To get here required a long and winding route. Refer a Friend and Earn One Month of Free Membership. In this conversation. Verified account Protected Tweets @ Protected Tweets @ On average, Wave Life Sciences executives and independent directors trade stock every 39 days with the average trade being worth of $949,631. These things have helped him get to where he is now one of the richest people on Earth. Pathos AI is currently in the works and attempting to raise about $40 million, per an SEC filing from this week. Bens wife, Keri, grew up on a red dirt road in small-town Georgia. Above is the net worth, insider trading, and ownership report for Kolchinsky Peter. Recently at Dyne Therapeutics, Inc, Peter Kolchinsky has sold an estimated value of $0 worth. 2004-2023 GuruFocus.com, LLC. This slide deck contains a powerful visual illustration of the biotech industry's race to find a cure for Hepatitis C. Run through the slide deck quickly to appreciate the sheer level of hustle that won the world a cure, and then more slowly to appreciate every move in the chess game of mergers & acquisitions. The most active traders at the company are In addition, he makes $151,598 as Independent Director at Wave Life Sciences. Quality, Value, Ownership Undervalued - Ebit/EV + B/M Blend Quality, Value, Momentum Activist Targets Dividend Yield Microcap with Revenue NCAV Screen Net Net Working Capital Negative Enterprise Value Piotroski Score ROIC Screen Short Volume Ratio High Insider Selling High Insider Buying October 20, 2021The vaccine business has long been a quiet and profitable game of kings.